Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind,

UQSC2 was as well tolerated as the authorized comparator vaccine and produced an equally robust boost in neutralizing immune response. These findings support the effectiveness of the MC2 platform in producing vaccines against newly emerging variants of SARS-CoV-2 and other respiratory viruses, as well as the platform's potential use in emergency response to novel viruses.

Authors

Institutions

Publication Details

Journal
The Journal of Infectious Diseases
Published
2025-11-10
DOI
https://doi.org/10.1093/infdis/jiaf568
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind,

Karen Hughes, Justin B. Goh, Marianne Gillard, Jillian Bennet et al.
The Journal of Infectious Diseases
SARS-CoV-2 and COVID-19 Research
article

Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18–55 Years: A Randomized, Double-Blind,

Karen Hughes, Justin B. Goh, Marianne Gillard, Jillian Bennet, Julia Lackenby, Alberto A. Amarilla, Daniel Watterson, Trent P. Munro, Keith J. Chappell, Kym Hoger, Vivian Kienzle, Nicolas Tardiota, Martina L. Jones, Benjamin Liang, Charani Ranasinghe, Jake S. O’Donnell, Zheyi Li, Benjamin Hughes, Rhiannon L. Dalrymple, Patrick C. Reading, Noushin Jaberolansar, Christina L Henderson, Paul R. Young, Kanta Subbarao, James Barnes, Francesca L. Mordant, Naphak Modhiran, Varsha Kommajosyula
article en

Abstract

UQSC2 was as well tolerated as the authorized comparator vaccine and produced an equally robust boost in neutralizing immune response. These findings support the effectiveness of the MC2 platform in producing vaccines against newly emerging variants of SARS-CoV-2 and other respiratory viruses, as well as the platform's potential use in emergency response to novel viruses.

The Journal of Infectious DiseasesVol. 233(2)
Australian National University (AU), The University of Queensland (AU), Peter Doherty Institute (AU), Oldham Council (GB)
Openalex Percentile: Top 57%
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.